Gergich, Kevin
Merck & Co., Inc., Rahway, NJ, USA (United States)
2 papers on CoChat
Most cited papers
- Verified
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 1,774
- Verified
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 1,069
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free